Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery

Sponsor
Capital Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT02132104
Collaborator
(none)
208
2
2
24
104
4.3

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate whether human amnion graft reduces the reformation of severe intrauterine adhesions (IUA) following hysteroscopic adhesiolysis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Uterine application of amnion membrane
  • Device: Foley balloon
  • Drug: Femoston
N/A

Detailed Description

Background

IUA is a consequence of trauma to the endometrium, producing partial or complete obliteration in the uterine cavity and/or the cervical canal, resulting in conditions such as menstrual abnormalities, infertility, and recurrent pregnancy loss. The outcome of hysteroscopic adhesiolysis for IUA is significantly affected by recurrence of intrauterine adhesions. The IUA research should be directed toward reduction of adhesion reformation with a view to improve outcome.

The reformation of intrauterine adhesions appears to be directly related to the severity of the adhesions. It has been reported that the recurrence rate for intrauterine adhesions ranges from 3.1% to 23.5% among all cases of intrauterine adhesions and from 20% to 62.5% in those with severe adhesions.

In this study, considering the high recurrent rate in severe IUA, investigator will focus on severe IUA cases.

Up to now several strategies are commonly employed by various investigators after division of intrauterine adhesions:

  1. Physical barriers have been used to promote regeneration of the endometrium and prevention of adhesions. The physical barriers include an intrauterine device (IUD), a Foley catheter, a number of modifications of hyaluronic acid and Auto-cross-linked hyaluronic acid gel.

  2. Hormonal treatment has been used to promote regeneration of the endometrium.

  3. Antibiotic therapy has been used to prevent infection which is a potent trigger for adhesion formation/reformation.

  4. Various medications have been described to increase vascular flow to endometrium, such as asprin, nitroglycerine and sildenafil citrate.

There is published data (Amer et al, 2010), which based on a plot prospective, randomised, comparative study that grafting of either fresh or dried amnion is a promising adjunctive procedure for decreasing recurrence of adhesions and encouraging endometrial regeneration after hysteroscopic lysis of severe intrauterine adhesions. However, the study had a small number of patients, the valid conclusion can not be drawn.

In this study, the aim is to compare the safety and the efficacy of insertion of intrauterine balloon + hormonal treatment with or without grafting amnion to prevent intrauterine adhesion formation/reformation following division of intrauterine adhesions.

Study Design

Patients with severe IUA are enrolled according to the classification of intrauterine adhesion by American Fertility Society.

208 patients with severe IUA were chosen at random and divided equally into those who received amnion graft, following hysteroscopic adhesiolysis (treatment groups) and to those who did not receive the amnion graft (control groups).

Intervention

Following hysteroscopic adhesiolysis, patients will be randomised to have a Foley balloon with or without amnion graft into the uterine cavity. Hormones therapy has been used after surgical treatment both in treatment groups and control groups. A second look and a third look hysteroscopy will be performed about 4 and 12 weeks after the initial operative hysteroscopy. The amount of adhesions, if any, during the initial and reexamine hysteroscopies will be scored.

Power calculation

The investigators' retrospective pilot study data showed that the recurrent rate of severe IUA is around 30% in amnion treatment groups, and around 47.5% in control groups. According to these data, investigators calculated the sample sizes of this study by using Cochran-Mantel-Haenszel test with software PASS 11. Investigators will recruit 104 patients in each group.

Group sample sizes of 104 in group one and 104 in group two achieve 85% power to detect a difference between the group proportions of -0.2000. The group two proportion is 0.5000. The group one proportion is assumed to be 0.5000 under the null hypothesis and 0.3000 under the alternative hypothesis. The test statistic used is the two-sided Z test (unpooled). The significance level of the test was targeted at 0.0500. The significance level actually achieved by this design is not available.

Statistics

Safety and efficacy were evaluated by software NCSS-PASS, using Two Independent Proportions (Non-Null Case) Power Analysis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
208 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Amnion Graft for Preventing Intrauterine Adhesions Following Hysteroscopic Surgery
Study Start Date :
Nov 1, 2014
Anticipated Primary Completion Date :
Aug 1, 2016
Anticipated Study Completion Date :
Nov 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: amnion graft in severe IUA

patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.

Procedure: Uterine application of amnion membrane
Uterine application of amnion membrane following hysteroscopic adhesiolysis.
Other Names:
  • Human amnion membrane
  • Device: Foley balloon
    Uterine application of Foley balloon

    Drug: Femoston
    Hormones treatment after surgery.
    Other Names:
  • Hormones
  • Sham Comparator: non-amnion graft in severe IUA

    patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.

    Device: Foley balloon
    Uterine application of Foley balloon

    Drug: Femoston
    Hormones treatment after surgery.
    Other Names:
  • Hormones
  • Outcome Measures

    Primary Outcome Measures

    1. safety of intrauterine application of amnion membrane [3 months]

      patients treated by amnion membrane following their hysteroscopic procedure were followed for immediate and late adverse effect: fever, abnormal vaginal discharge, pelvic pain, increased intrauterine adhesion formation upon follow up and changes in menstrual pattern.

    Secondary Outcome Measures

    1. efficacy of intrauterine application of amnion graft in reducing adhesion formation following hysteroscopic adhesiolysis. [3 months]

      intrauterine adhesions were assessed and graded according to the American Fertility Society (AFS) score upon hysteroscopy follow up 4 and 12 weeks following initial treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • patients scheduled for adhesiolysis of intrauterine adhesions

    • patients willing to undergo followed hysteroscopy about 4 and 12 weeks after the surgery to assess the reformation of intrauterine adhesions.

    • Written, informed consent obtained.

    Exclusion Criteria:
    • ongoing pregnancy

    • Peroperative fever or infections

    • Malignancy

    • Precious pelvic inflammatory disease

    • Uterine fibroid (>3cm size)

    • endometriosis

    • Contraindications for anesthesia

    • Not able to read and/or understand informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fu Xing Hospital, Capital Medical University Beijing China 100038
    2 Fu Xing Hospital, Capital Medical University Beijing China 100038

    Sponsors and Collaborators

    • Capital Medical University

    Investigators

    • Study Director: TC Li, PhD, Hysteroscopic Center, Fu Xing Hospital
    • Principal Investigator: Xuebing Peng, MD, Hysteroscopic Center, Fu Xing Hospital
    • Study Chair: Enlan Xia, MD, Hysteroscopic Center, Fu Xing Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    XUEBING PENG, Associated Professor, Capital Medical University
    ClinicalTrials.gov Identifier:
    NCT02132104
    Other Study ID Numbers:
    • CMU-FXH-14-06
    First Posted:
    May 7, 2014
    Last Update Posted:
    Oct 21, 2014
    Last Verified:
    Oct 1, 2014
    Keywords provided by XUEBING PENG, Associated Professor, Capital Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 21, 2014